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ABSTRACT
The proarrhythmic potency of drugs is usually attributed to the IKr current block. During safety pharmacology testing analysis of
IKr in cardiomyocytes was replaced by human ether-a-go-go-related gene (hERG) test using automated patch-clamp systems in stable
transfected cell lines. Aim of this study was to compare the effect of proarrhythmic compounds on hERG and IKr currents and on
cardiac action potential. The hERG current was measured by using both automated and manual patch-clamp methods on
HEK293 cells. The native ion currents (IKr, INaL, ICaL) were recorded from rabbit ventricular myocytes by manual patch-clamp
technique. Action potentials in rabbit ventricular muscle and undiseased human donor hearts were studied by conventional
microelectrode technique. Dofetilide, cisapride, sotalol, terfenadine, and verapamil blocked hERG channels at 37C with an IC50 of
7 nM, 18 nM, 343 lM, 165 nM, and 214 nM, respectively. Using manual patch-clamp, the IC50 values of sotalol and terfenadine
were 78 mM and 31 nM, respectively. The IC50 values calculated from IKr measurements at 37C were 13 nM, 26 nM, 52 lM, 54 nM,
and 268 nM, respectively. Cisapride, dofetilide, and sotalol excessively lengthened, terfenadine, and verapamil did not influence
the action potential duration. Terfenadine significantly inhibited INaL and moderately ICaL, verapamil blocked only ICaL.
Automated hERG assays may over/underestimate proarrhythmic risk. Manual patch-clamp has substantially higher sensitivity to
certain drugs. Action potential studies are also required to analyze complex multichannel effects. Therefore, manual patch-
clamp and action potential experiments should be a part of preclinical safety tests.
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Life threatening cardiac arrhythmias and sudden cardiac death
caused by drugs are one of the major safety issues for pharma-
ceutical industry and regulatory agencies (Polonchuk, 2012). In
the past, several drugs such as cisapride, grepafloxacin, terfena-
dine, and terodiline have been withdrawn from major markets
because of their proarrhythmic effect (Hishigaki and Kuhara,
2011; Varro and Baczko, 2011). The therapeutic use of these
agents, in the worst case, has led to ventricular fibrillation-in-
duced cardiac arrest and consequently sudden cardiac death.
Furthermore, drug withdrawn from the market is particularly
costly and may harm the prestige of the company as well (Farre
et al., 2007).
Many of drugs and potential drug candidate molecules exert
their arrhythmogenic effects through the Kv11.1 voltage-gated
potassium ion channel encoded by the human ether-a-go-go-
related gene (hERG, KCNH2) (Alexander et al., 2011). This pore-
forming protein expressed in ventricular cardiocytes, and repre-
sents the a-subunit of the ion channel responsible for rapid
delayed rectifier potassium current (IKr) (Sanguinetti et al., 1995;
Trudeau et al., 1995). hERG channel has been found extremely
promiscuous in its interactions with a wide range of pharmaco-
logical entities (Farre et al., 2007). The IKr current plays a funda-
mental role in the phase 3 of repolarization of the action
potential; therefore, inhibition of hERG channel delays cardiac
action potential repolarization, which lengthens the action po-
tential duration (APD). The drug-induced repolarization delay
might associate with catastrophic polymorphic ventricular
tachycardia (torsades de pointes, TdP). This mechanism is the
basis of fatal ventricular fibrillation and sudden death (Hancox
et al., 2008; Lengyel et al., 2007; Yap and Camm, 2003). Based on
this concept investigation of IKr blocking and action potential re-
polarization duration lengthening capabilities became of re-
quired item of safety pharmacology profile of drugs. At present,
to avoid severe cardiotoxicity, every new compound is to go
through preclinical safety testing determined by the U.S. Food
and Drug Administration, the European Medicines Agency and
other regulatory entities. Preclinical studies have to be carried
out according to the International Conference on
Harmonization’s S7B guideline. In vitro electrophysiological
experiments require on cardiac action potential and/or cardiac
ionic currents, whereas in vivo studies can directly demonstrate
the drug-induced QT interval prolongation.
Among the in vitro assays, repolarization lengthening effect
of the investigational compounds can be adequately analyzed
with conventional microelectrode technique in different cardiac
structures such as Purkinje fibers and papillary muscles. This
method allows the direct observation the alterations of cardiac
action potential waveform in cellular level, but gives no specific
information about the currents pass through different types of
ion channels (Hodgkin and Huxley, 1945). Today, ion channel
function and transmembrane ionic currents such as IKr are
most precisely studied using the conventional manual patch-
clamp technique (Neher and Sakmann, 1976; Neher et al., 1978).
By this method, measurement of the activity of individual chan-
nels or the entire ion channel population of the cell is routinely
achievable. This technique has become the “gold standard” in
studying ion channel behavior, function, kinetics, and pharma-
cology, mainly in native mammalian cells (Dabrowski et al.,
2008; Dunlop et al., 2008; Farre and Fertig, 2012; Farre et al., 2007,
2008; Fertig et al., 2002). The conventional microelectrode tech-
nique and the manual patch-clamp method offer direct, infor-
mation-rich, and real-time in vitro technologies to study
proarrhythmic effect of drugs and drug candidate compounds.
Although providing excellent data quality, these tests are
complicated, time consuming and expensive for the large num-
bers of compounds before the extensive pharmacodynamic
experiments can be initiated, because they require the continu-
ous presence of highly skilled and trained personnel. Therefore,
these problems excludes the aforementioned techniques as
screening tools in early drug development and optimization
(Dabrowski et al., 2008; Dunlop et al., 2008; Farre and Fertig, 2012;
Farre et al., 2007, 2009). In recent years, numerous companies
have developed and introduced automated patch-clamp plat-
forms for high-throughput screening, which are mainly used
with stably expressing cell lines and suitable for rapid and high
quality optimization of drug candidates. The breakthrough in
automated electrophysiology came when planar patch-clamp
method without micromanipulation or visual control was
launched (Fertig et al., 2002; Lu¨ and An, 2008). This innovative
technology facilitates functional data on ion channel active
compounds with the throughput capability that is significantly
higher compared with conventional techniques (Dunlop et al.,
2008; Farre and Fertig, 2012; Farre et al., 2007, 2009). Therefore,
analysis of IKr current in heart muscle cells was typically
replaced by the examination of its recombinant equivalent
hERG current using automated patch-clamp systems and stable
transfected cell lines.
However, more and more evidence indicates that the differ-
ent proarrhythmic pharmacological assays result in contradic-
tory outcomes raising serious questions regarding their
predictability for in vivo situations including clinical settings.
Assays often give false-positive and -negative results or over/
underestimate the cardiac proarrhythmic effect. Therefore, aim
of this study was to compare the effect of different known
proarrhythmic compounds on hERG and IKr currents and on car-
diac action potential to determine the value of in vitro assays in
evaluation of cardiac proarrhythmic risk of these compounds
and help to understand the nature of proarrhythmic pharmaco-
logical safety drug tests.
MATERIALS ANDMETHODS
Chemicals
All chemicals, which are not specifically indicated, were pur-
chased from Sigma-Aldrich Ltd (Budapest, Hungary). To study
the effect of dofetilide, cisapride monohydrate, terfenadine, and
verapamil, stock solutions were prepared from these com-
pounds, where the concentrations were 10 mM and the sol-
ubilizing agent was dimethyl sulfoxide (DMSO). Aliquots were
stored at 20C for up to 2–4 weeks. (6)-Sotalol hydrochloride
was acquired from Sequoia Research Products Ltd (Pangbourne,
UK). Sotalol was dissolved directly in external solution at 10 mM
concentration before experiments. For electrophysiological
measurements, stock solutions were further diluted with exter-
nal solution, to give appropriate concentrations for the patch-
clamp experiments. The final DMSO concentrations in the
tested samples were 1% or less.
Ethics Statement and Species
Patients. Hearts were obtained from organ donors whose nondi-
seased hearts were explanted to obtain pulmonary and aortic
valves for transplant surgery. Before cardiac explantation, organ
donors did not receive medication apart from dobutamine, furo-
semide, and plasma expanders. The investigations conformed
to the principles of the Declaration of Helsinki. Experimental pro-
tocols were approved by the National Scientific and Research
Ethical Review Boards (4991-0/2010-1018EKU [339/PI/010]).
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Animals. All experiments were carried out in compliance with
the Guide for the Care and Use of Laboratory Animals (USA NIH pub-
lication NO 85-23, revised 1996) and conformed to the Directive
2010/63/EU of the European Parliament. The protocols have
been approved by the Ethical Committee for the Protection of
Animals in Research of the University of Szeged, Szeged,
Hungary (approval number: I-74-5-2012) and by the Department
of Animal Health and Food Control of the Ministry of
Agriculture and Rural Development (authority approval number
XIII/1211/2012).
Conventional Microelectrode Technique
Action potentials were recorded in ventricular trabeculae and
papillary muscle preparations obtained from the right ventricles
of rabbit or from undiseased human donor hearts using conven-
tional microelectrode techniques. New Zealand rabbits of either
sex weighing 2–3 kg were sacrificed by cervical dislocation after
an intravenous injection of 400 U/kg heparin. Then the chest
was opened, and the heart was rapidly removed. The heart was
immediately rinsed in oxygenated modified Locke’s solution
containing (in mM): NaCl 128.3, KCl 4, CaCl2 1.8, MgCl2 0.42,
NaHCO3 21.4, and glucose 10. The pH of this solution was set be-
tween 7.35 and 7.4 when gassed with the mixture of 95% O2 and
5% CO2 at 37C. In case of human donor hearts, after explanta-
tion, each heart was perfused with cardioplegic solution and
kept cold (4–6C) for 2–4 h before dissection.
Isolated muscle preparations obtained from the right ventri-
cle were individually mounted in a tissue chamber with the
volume of 50 ml. Each preparation was initially stimulated
through a pair of platinum electrodes in contact with the prepa-
ration using rectangular current pulses of 2 ms duration. These
stimuli were delivered at a constant cycle length of 1000 ms for
at least 60 min allowing the preparation to equilibrate before
the measurements were initiated. Transmembrane potentials
were recorded using conventional glass microelectrodes, filled
with 3 M KCl and having tip resistances of 5–20 MX, connected
to the input of a high impedance electrometer (Experimetria,
type 309, Budapest, Hungary) which was coupled to a dual beam
oscilloscope. The resting potential (RP), action potential ampli-
tude (APA), maximum upstroke velocity (Vmax), and APD mea-
sured at 50% and 90% of repolarization (APD50 and APD90,
respectively) were off-line determined using a home-made soft-
ware (APES) running on a computer equipped with an ADA 3300
analog-to-digital data acquisition board (Real Time Devices,
Inc., State College, Pennsylvania) having a maximum sampling
frequency of 40 kHz. Stimulation with a constant cycle length of
1000 ms was applied in the course of all experiments. Attempts
were made to maintain the same impalement throughout each
experiment. In case an impalement became dislodged, adjust-
ment was attempted, and if the action potential characteristics
of the re-established impalement deviated by less than 5% from
the previous measurement, the experiment continued (Jost
et al., 2005; Kristof et al., 2012; Lengyel et al., 2001; Orvos et al.,
2015). All measurements were carried out at 37C.
Conventional Manual Patch-clamp Measurements
Left ventricular myocytes were enzymatically dissociated from
hearts of New Zealand rabbits of either sex weighing 2–3 kg us-
ing the retrograde perfusion technique. The chest is opened and
the heart is quickly removed and placed into cold (4–8C) solu-
tion with the following composition (in mM): NaCl 135, KCl 4.7,
KH2PO4 1.2, MgSO4 1.2, HEPES 10, NaHCO3 4.4, Glucose 10, CaCl2
1 (pH 7.2). The heart is then mounted on a modified, 60 cm high
Langendorff column and perfused with oxygenated perfusate of
the same composition warmed to 37C. After 3–5 min of perfu-
sion to flush blood from the coronary vasculature, the perfusate
is switched to one having no exogenously added calcium (ie, to
one that is nominally Ca2þ-free) until the heart cease contract-
ing (8 to 10 min). Enzymatic digestion is accomplished by per-
fusion with the same, nominally Ca2þ-free solution with 260 U/
ml Collagenase (Worthington Type 2) and 33 mM CaCl2. After 10–
15 min the heart is removed from the aortic cannula and placed
into enzyme free solution containing 1 mM CaCl2 warmed to
37C for 15 min. Then, the tissue is minced into small chunks,
and following gentle agitation myocytes are separated by filter-
ing the resulting slurry through a nylon mesh. Myocytes are fi-
nally harvested by gravity sedimentation. Once the majority of
individual myocytes has settled to the bottom of the container,
the supernatant is decanted and replaced with Tyrode’s solu-
tion and the myocytes are resuspended by gentle agitation. This
procedure is repeated twice more and the resulting myocyte
suspension is stored in HEPES buffered Tyrode’s solution at
room temperature.
One drop of cell suspension was placed in a transparent re-
cording chamber mounted on the stage of an inverted micro-
scope. The myocytes were allowed to settle and adhere to the
bottom for at least 5–10 min before superfusion was initiated
with Tyrode solution containing (in mM): NaCl 144, NaH2PO4 0.4,
KCl 4.0, CaCl2 1.8, MgSO4 0.53, glucose 5.5, and HEPES 5.0 (pH 7.4,
NaOH). Temperature was set to 37C. Only rod-shaped cells
with clear cross-striations were used. Patch-clamp micropip-
ettes were fabricated from borosilicate glass capillaries using a
micropipette puller (Flaming/Brown, type P-97, Sutter Co,
Novato, California). These electrodes had resistances between
1.5 and 2.5 MX. Membrane currents were recorded with
Axopatch 200B patch-clamp amplifiers (Molecular Devices, Inc.,
Sunnyvale, California) using the whole-cell configuration of the
patch-clamp technique. After establishing a high resistance (1–
10 GX) seal by gentle suction, the cell membrane beneath the tip
of the electrode was disrupted by suction or application of short
electrical pulses. Membrane currents were digitized after low-
pass filtering at 1 kHz using analog-to-digital converters
(Digidata 1440 A, Molecular Devices, Inc.) under software control
(pClamp 10, Molecular Devices, Inc.). The same software was
used for off-line analysis (Kristof et al., 2012).
When measuring rapid delayed rectifier potassium cur-
rents (IKr), pipette solution was contained (in mM): KOH 110,
KCl 40, K2ATP 5, MgCl2 5, EGTA 5, HEPES 10 (pH was adjusted to
7.2 by aspartic acid). Nisoldipine (1 mM) was added to the exter-
nal solution to eliminate L-type Ca2þ current (ICaL). The slow
component of the delayed rectifier potassium current (IKs) was
inhibited by using the selective IKs blocker HMR 1556 (0.5 mM).
IKr was activated by 1000 ms long depolarizing voltage pulses
with the pulse frequency of 0.05 Hz to the test potential of 20
mV and then the cell was repolarized to 40 mV. The deacti-
vating tail current at 40 mV after the test pulse was assessed
as IKr. The amplitudes of the IKr tail currents were determined
as the difference between the peak tail current and the base-
line (Lengyel et al., 2001). Before the depolarizing test pulse 500
ms long prepulse to 40 mV was applied to ensure the base-
line region. The holding potential was 80 mV. After control
period, maximum 2 increasing concentrations of the test com-
pound were applied, each for approximately 6–8 min (in case
of dofetilide 10 min). Unlike during IKr measurements in native
myocytes, the solutions and the voltage protocol for manual
patch-clamp experiments on HEK-hERG cell line were the
same as used during automated patch-clamp experiments
(see below).
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The L-type calcium current (ICaL) was recorded in HEPES-
buffered Tyrode’s solution supplemented with 3 mM 4-amino-
pyridine. A special solution was used to fill the micropipettes
(composition in mM: CsCl 125, TEACl 20, MgATP 5, EGTA 10,
HEPES 10, pH was adjusted to 7.2 by CsOH). ICaL was evoked by
400 ms long depolarizing voltage pulses to various test poten-
tials ranging from 35 to 40 mV. The holding potential was 80
mV. A short prepulse of 40 mV served to inactivate Naþ cur-
rent. The amplitude of the ICaL was defined as the difference be-
tween the peak inward current at the beginning of the pulse
and the current at the end of the pulse (Jost et al., 2013).
The late sodium current (INaL) was activated by depolarizing
voltage pulses to 20 mV from the holding potential of 120
mV. After 5–7 min incubation with terfenadine the external so-
lution was replaced by that containing 20 lM tetrodotoxin
(TTX). TTX at this concentration completely blocks the late so-
dium current. The external solution was HEPES-buffered
Tyrode’s solution supplemented with 1 lM nisoldipine, 0.5 lM
HMR-1556, and 0.1 lM dofetilide to block ICaL, IKs, and IKr cur-
rents. The composition of the pipette solution (in mM) was:
KOH 110, KCl 40, K2ATP 5, MgCl2 5, EGTA 5, HEPES 10 (pH was ad-
justed to 7.2 by aspartic acid) (Kohajda et al., 2016).
Automated Planar Patch-clamp Measurements
The hERG channel current was measured by using planar
patch-clamp technology in the whole-cell configuration with a
4 channel medium-throughput fully automated patch-clamp
platform (Patchliner Quattro, Nanion Technologies GmbH,
Munich, Germany) with integrated temperature control. Data
acquisition and online analysis were performed with an EPC-10
Quadro patch-clamp amplifier (HEKA Elektronik Dr Schulze
GmbH, Lambrecht/Pfalz, Germany), using PatchMaster 2.65 soft-
ware (HEKA Elektronik Dr. Schulze GmbH). The pipetting proto-
cols were controlled by PatchControlHT 1.09.30 software
(Nanion Technologies GmbH).
Experiments were carried out at room or physiological (37C)
temperature, on HEK293 (human embryonic kidney) cells stably
expressing the hERG (Kv11.1) potassium channel. The cell line
originated from Cell Culture Service GmbH (Hamburg,
Germany). Cells were cultured at 37C, in 5% CO2 in IMDM me-
dium (PAA Laboratories GmbH, Pasching, Austria) supple-
mented with 10% FBS (PAA Laboratories GmbH), 2 mM L-
glutamine (Life Technologies Corporation, Carlsbad, California),
1 mM Na-piruvate (PAA Laboratories GmbH), and 500 mg/ml
G418 (PAA Laboratories GmbH). Suspension of cells was used for
measurements from running cell culture. Cells were washed
twice with PBS (Life Technologies Corporation) and then de-
tached with trypsin-EDTA (PAA Laboratories GmbH) for 30–60 s
before the measurement. Trypsin was blocked with the serum-
containing medium. The cell suspension was next centrifuged
(2 min, 100  g), resuspended in IMDM medium at a final den-
sity of 1  106–5  106 cells/ml, and kept in the cell hotel of the
Patchliner. Cells were recovered after 15–30 min and remained
suitable for automated patch-clamp recordings for up to 4 h.
The following solutions were used during patch-clamp re-
cording (compositions in mM): internal solution: KCl 50, NaCl
10, KF 60, EGTA 20, HEPES 10, pH 7.2 (KOH); external solution:
NaCl 140, KCl 4, glucose-monohydrate 5, MgCl2 1, CaCl2 3, HEPES
10, pH 7.4 (NaOH). All solutions were sterile filtered. Aliquots
were stored at 20C and warmed up to room temperature be-
fore use. The voltage protocol for hERG ion channel started with
a short (100 ms) 40 mV step to establish the baseline region. A
depolarizing step was applied to the test potential of 20 mV for
3 s, and then the cell was repolarized to 40 mV to evoke
outward tail current. Holding potential was 80 mV. The pulse
frequency was approximately 0.1 Hz. Currents were low-pass
filtered at 2.9 kHz using the internal Bessel filter of the EPC-10
Quadro patch-clamp amplifier (HEKA Elektronik Dr. Schulze
GmbH) and digitized at 10 kHz. The peak tail current was cor-
rected the leak current defined during the first period to 40
mV. Recording started in external solution. After this control pe-
riod, 6 increasing concentrations of the test compound were ap-
plied, each for approximately 3 min (in case of dofetilide 6 min)
to record a complete concentration-response curve.
Amitriptyline (10 mM) was applied as a reference inhibitor then
a wash-out step terminated the protocol.
Statistics
All data are expressed as means 6 SEM. The “n” number refers
to the number of experiments (ie, the number of cells in case of
patch-clamp and the number of ventricular muscle prepara-
tions—papillary or trabecular muscle—in case of action poten-
tial measurements) except native IKr measurements when it
refers to the number of experiments regarding 1 data point of
the concentration-response curve and the means 6 SEM values
were calculated accordingly. Statistical analysis was performed
with Student’s t test for paired data or one-way analysis of vari-
ance (ANOVA). The results were considered statistically signifi-
cant when p was <.05.
RESULTS
All compounds (dofetilide, cisapride, sotalol, terfenadine, and
verapamil) were tested in hERG assay at both room temperature
and 37C with automated patch-clamp system. The elevation of
ambient temperature to physiologic significantly altered the
characteristic of hERG current. The current density of peak tail
current increased from 21.97 6 0.40 pA/pF to 32.42 6 0.69 pA/pF
(n ¼ 19–24, p < .05). The rise time of tail current was decreased
and the time constant of decay phase was more rapid (tau
changed from 761.52 6 16.77 ms to 394.15 6 8.69 ms, n ¼ 19–23,
p < .05).
All investigated compounds inhibited the hERG current at
both temperatures. The IC50 values of the dofetilide elicited in-
hibition were very similar (8.4 6 0.2 nM, n ¼ 6 at room tempera-
ture and 7.3 6 0.2 nM, n ¼ 5 at 37C). The other compounds
displayed different properties at room temperature versus
physiological temperature (37C). Cisapride, sotalol, terfena-
dine, and verapamil blocked hERG channels at room tempera-
ture with an IC50 of 47.5 6 4.8 nM, n ¼ 5; 773.7 6 9.3 lM, n ¼ 5;
266.0 6 26.8 nM, n ¼ 6; and 344.9 6 26.1 nM, n ¼ 5, respectively.
However, at 37C these compounds found to be much more po-
tent (IC50 values were 17.7 6 2.9 nM, n ¼ 5; 342.8 6 24.8 lM, n ¼
5; 165.4 6 24.5 nM, n ¼ 6; and 213.6 6 22.5 nM, n ¼ 5,
respectively).
To evaluate the prognostic value of hERG assay these agents
were subjected for further investigations. The IKr current block-
ing capability of the compounds was tested on rabbit ventricu-
lar myocytes with manual patch-clamp method at 37C. The
corresponding IC50 values of dofetilide, cisapride, and verapamil
were 13.0 6 2.6 nM (n ¼ 3–4), 26.4 6 4.5 nM (n ¼ 3–5), and 268.2 6
11.2 nM (n ¼ 4–5), respectively, showing a good correlation with
IC50 values obtained in hERG assays. On the contrary, IC50 val-
ues derived from IKr measurements was approximately 7 and 3
times lower (51.66 8.8 lM, n ¼ 2–6 and 54.36 5.2 nM, n ¼ 3–4, re-
spectively) in case of sotalol and terfenadine. The results of
both automated and manual patch-clamp experiments are
shown in Figures 1–5 and Table 1.
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As sotalol and terfenadine have stronger effect on IKr mea-
sured by manual patch-clamp method compared with hERG au-
tomated patch-clamp experiments, the effects of these drugs on
hERG current using manual patch-clamp technique at 37C
were also investigated to study how the potency of these drugs
are influenced by the experimental techniques themselves. In
contrast with the hERG automated patch-clamp assays, the
effects of sotalol and terfenadine on hERG current were stronger
measured by the manual patch-clamp technique: IC50 values
calculated from the hERG manual patch-clamp experiments
were 77.5 6 4.8 mM (n ¼ 3–7) and 31.0 6 3.2 nM (n ¼ 3–5), respec-
tively, showing still somewhat different but far less discrepancy
with the native IKr measurements (Figs. 3 and 4).
To study the safety pharmacology consequences of the hERG
and IKr inhibition of dofetilide, cisapride, sotalol, terfenadine,
and verapamil, the effect of these compounds on action poten-
tial configuration was studied in rabbit right ventricular papil-
lary muscle preparations. In these investigations, the IC50
concentrations obtained from IKr experiments were applied.
Dofetilide, cisapride, and sotalol significantly lengthened the
APD at stimulation cycle length of 1000 ms. The prolongation
of APD90 was 47.8 6 12.9% (n ¼ 7) in case of 13 nM dofetilide,
68.4 6 10.0% (n ¼ 6) in case of 26 nM cisapride, whereas 52 lM
sotalol extended the APD with 56.0 6 4.6% (n ¼ 5). Verifying by
one-way ANOVA these APD lengthenings were not significantly
different. In contrast, terfenadine (1.4 6 3.0%, n ¼ 8) and verapa-
mil (0.6 6 1.8%, n ¼ 5) did not significantly affect the APD at 54
and 270 nM concentrations, respectively (Figure 6 and Table 2).
As terfenadine and verapamil did not influence the action
potential repolarization, the possible effects of these com-
pounds on the late Naþ current (INaL) and on the L-type inward
calcium current (ICaL) were also investigated in rabbit ventricu-
lar myocytes. These experiments clearly revealed that terfena-
dine at 54 nM concentration significantly inhibited INaL
(Figure 7, from 82.8 6 17.9 pA to 45.8 6 7.9 pA, n ¼ 4, p < .05 at
20 mV test potential). A slight but significant block on ICaL by
54 nM terfenadine was also observed (Figure 8). Verapamil at
270 nM did not influenced the INaL current (control: 56.5 6 11.2
pA, drug: 49.0 6 9.2 pA, n ¼ 4, not significant, see Figure 7),
whereas a moderate but significant inhibition of ICaL current
was observed after application of 270 nM verapamil (Figure 8).
In purpose to confirm our findings in rabbit ventricular myo-
cytes, effect of dofetilide, cisapride, sotalol, terfenadine, and ve-
rapamil were also studied on action potential repolarization in
Figure 1. Effect of dofetilide on hERG and IKr current. A, Example traces for hERG mediated currents obtained from HEK-hERG cell treated with 10 nM dofetilide at room
temperature (RT). B, Effect of 10 nM dofetilide on hERG current at 37C. C, Sample IKr current sweeps obtained from rabbit left ventricular muscle cell treated with 10
nM dofetilide. The currents were recorded using the voltage protocols shown at the top of panels (A–C). D, Dose-response curves of dofetilide derived from hERG meas-
urements at RT and at 37C and from IKr experiments. Abbreviations: APC, automated patch-clamp; MPC, manual patch-clamp.
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undiseased human ventricular muscle. As Figure 9 shows, 10
nM dofetilide, 30 nM cisapride, and 30 lM sotalol markedly
lengthened the APD at stimulation cycle length of 1000 ms. The
prolongation of APD90 was 20.4 6 4.5% (n ¼ 7), 27.5 6 9.8% (n ¼
3), and 28.0 6 1.8% (n ¼ 6), respectively. These values were not
significantly different. However, terfenadine even at high 1 lM
concentration did not influence the APD at 90% of repolarization
(Table 3). Verapamil at 300 nM concentration in 2 experiments
did not affect the action potential repolarization in undiseased
human right ventricular muscle preparations (Figure 9).
DISCUSSION
Because there are important and not well understood differen-
ces between the evaluation of proarrhythmic ability with high-
throughput hERG channel, IKr or action potential experiments,
we have studied the effect of 5 drugs with established proar-
rhythmic potential (dofetilide, cisapride, sotalol, terfenadine,
and verapamil) on hERG current (at room temperature and
37C), on IKr current (37C), and on rabbit and human cardiac ac-
tion potential comparing these assays and helping the rational
use of these proarrhythmic pharmacological safety drug tests
during preclinical drug development.
Current responses of cells expressing the hERG channel at
room temperature and physiological temperature were similar
in case of dofetilide. The most noticeable effects of raising the
temperature to 37C were that the peak amplitude was in-
creased, the rise time was decreased and the time constant of
decay phase was faster. Despite that, the dose-response curve
generated an IC50 similar to that obtained at room temperature,
and similar to that determined in the IKr experiments. In
addition, these data are in good agreement with our action po-
tential measurements and with previously published data (Mo
et al., 2009; Pearlstein et al., 2003; Weerapura et al., 2002).
Conversely, cisapride, sotalol, terfenadine, and verapamil
display different potencies at room temperature and 37C. All
these compounds were more potent at physiological tempera-
ture and therefore, it is a desirable option to study hERG cur-
rents at physiological temperature (Windley et al., 2018). In spite
of that, the majority of the commercially available patch-clamp
platforms have no integrated temperature control. Apart from
the differences in temperature cisapride—like dofetilide—
reduced IKr current and extended the action potential as
expected based on hERG measurements, and results are in good
agreement with literature (Drolet et al., 1998; Fossa et al., 2004;
Martin et al., 2004; Polonchuk, 2012).
Figure 2. Effect of cisapride on hERG and IKr current. A, Sample hERG current curves obtained from HEK-hERG cell treated with 30 nM cisapride at room temperature
(RT). B, Effect of 30 nM cisapride on hERG current at 37C. C, Representative IKr current sweeps obtained from rabbit left ventricular muscle cell treated with 30 nM cis-
apride. The currents were recorded using the voltage protocols shown at the top of panels (A–C). D, Dose-response curves of cisapride derived from hERG measure-
ments at RT and at 37C and from IKr experiments. Abbreviations: APC, automated patch-clamp; MPC, manual patch-clamp.
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However, verapamil blocked IKr current with an IC50 value
with similar to that calculated from hERG measurements at
37C but the drug did not lengthen the action potential in rabbit
right ventricular preparations. Other studies also reported sub-
micromolar IC50 of verapamil for hERG current (Chouabe et al.,
1998; Zhang et al., 1999). Zhang et al. (1997) described that 1 mM
verapamil suppress IKr tail current by 49% in guinea-pig.
Unlike the other drugs investigated in this study, sotalol and
terfenadine showed significantly greater degree of inhibition on
IKr current compared with hERG. In the literature, majority of
publications—using mainly manual patch-clamp—reported IC50
values for terfenadine between 10 and 60 nM in hERG cell lines,
which are much lower than that found in this study. However,
higher IC50 values have also been reported—for example 950 nM
(Abi-Gerges et al., 2011; automated patch-clamp) or 204 nM
(Crumb, 2000; manual patch-clamp), and others (Aslanian et al.,
2009; Limberis et al., 2006). These later studies used mainly auto-
mated patch-clamp method.
In manual patch-clamp, test solutions are usually prepared in
relatively large quantities directly before the experiments, and
are continuously perfused. In automated platforms, compound
plates with minor volume are used, and comparatively small
volumes of test solutions are applied to the cells. One may specu-
late that the adverse surface-to-volume ratio in compound plates
and microchannels and the increased incubation time can lead to
possible reduction of compound concentrations, especially in
case of hydrophobic, “sticky” agents such as terfenadine.
Adhesion and precipitation have been identified as the major
sources of potential right-shifted less accurate dose-response
curves (Mathes, 2006; Mo et al., 2009; Mo¨ller and Witchel, 2011),
which correspond to the literature data (Carmeliet, 1998; Limberis
et al., 2006; Salata et al., 1995). Our experiments showed that the
effect of terfenadine on hERG current was stronger measured by
the manual patch-clamp technique. The calculated IC50 value
was similar or even lower (31 vs 54 nM) to that of found in IKr
measurements, which seems to support the assumption
explained above. Therefore, the lower efficacy of terfenadine for
hERG found in our automated patch-clamp experiments may not
reflect the real potency of the drug. In contrast to terfenadine,
sotalol is among the least hydrophobic compounds (Mo et al.,
2009), and numerous studies also reported extremely high IC50
values in hERG cell lines utilized for manual patch-clamp (the
half-blocking concentrations of sotalol were 268–1200 lM in these
experiments [Abi-Gerges et al., 2011; Guth et al., 2004; Kirsch
Figure 3. Effect of sotalol on hERG and IKr current. A, Representative hERG current curves obtained from HEK-hERG cell treated with 100 lM sotalol at room temperature
(RT). B, Effect of 100 lM sotalol on hERG current at 37C. C, Representative IKr current curves obtained from rabbit left ventricular muscle cell treated with 100 lM sota-
lol. D, Representative hERG current curves obtained from HEK-hERG cell treated with 100 mM sotalol using manual patch-clamp technique. The currents were recorded
using the voltage protocols shown at the top of panels (A–D). E, Concentration-response curves of sotalol obtained from hERG experiments at RT, at 37C using auto-
mated and manual patch-clamp techniques and from IKr measurements. Abbreviations: APC, automated patch-clamp; MPC, manual patch-clamp.
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et al., 2004; Perrin et al., 2008; Vormberge et al., 2006]), therefore,
this explanation is unlikely. However, IC50 value of sotalol calcu-
lated from our hERG manual patch-clamp experiments was 77.5
mM showing distinct but moderate difference with the IKr meas-
urements and it was much less than the corresponding IC50 value
for automated patch-clamp hERG test. In addition a few study ob-
served similar IC50 values for sotalol as such 111 mM (Kramer
et al., 2013) and 86 mM (Crumb et al., 2016). Therefore, beyond the
high surface-to-volume ratio of recording chips used for auto-
mated patch-clamp measurements there should be other impor-
tant factors, which influence the measurements differently in
automated and manual patch-clamp methods.
Also as a possible alternative explanation, the moderate dif-
ferences between cell line and native myocyte measurements
may be due to possible allosteric interaction caused by drugs
used in native myocyte but not in cell line measurements for
current separation as it was suggested with other organic com-
pound with dofetilide-induced IKr/hERG inhibition (Yu et al.,
2016).
Complex nature of the composition of IKr channels may also
elucidate the difference in potency of sotalol and terfenadine
for hERG and native IKr found in our study. Increasing evidence
indicates that the a-subunit composition of the channel can
affects its blocking sensitivity. The hERG1 gene encodes at least
2 transcripts: hERG1a, the original isolate, and hERG 1b, an alter-
nate transcript (Lees-Miller et al., 1997; London et al., 1997). The
most of hERG screens have been conducted using recombinant
cell lines expressing only the hERG 1a subunit, although native
ventricular IKr channels are heteromers containing both hERG
1a and 1b subunits (Jones et al., 2004). Although the potency of
most compounds (including sotalol) was similar for the 2 tar-
gets, some differences were observed (dofetilide, E-4031 and
particularly fluoxetine). Some drugs were more potent at block-
ing hERG 1a/1b than 1a channels, others exerted greater inhibi-
tory effects on hERG 1a compared with 1a/1b channels. Thus,
the existing hERG 1a assays may underestimate the risk of
some drugs and overestimate the risk of others (Abi-Gerges
et al., 2011; Sale et al., 2008). Also, studies have identified addi-
tional interacting proteins affecting hERG drug sensitivity. For
example, MinK, MiRPs, and KCR1 coassembles with a pore-
forming subunit to create stable complexes whose functional
characteristics are similar to the native cardiac potassium
Figure 4. Effect of terfenadine on hERG and IKr current. A, Representative hERG current sweeps obtained from HEK-hERG cell treated with 100 nM terfenadine at room
temperature (RT). B, Effect of 100 nM terfenadine on hERG current at 37C. C, Representative IKr current curves obtained from rabbit left ventricular muscle cell treated
with 100 nM terfenadine. D, Representative hERG current curves obtained from HEK-hERG cell treated with 100 nM terfenadine using manual patch-clamp technique.
The currents were recorded using the voltage protocols shown at the top of panels (A–D). E, Concentration-response curves of terfenadine obtained from hERG experi-
ments at RT, at 37C using automated and manual patch-clamp techniques and from IKr measurements. Abbreviations: APC, automated patch-clamp; MPC, manual
patch-clamp.
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channel, adding another level of complexity to mechanisms
may affect cardiac safety pharmacology. Their expression and
modulation by sotalol could play an important role in determin-
ing the amount and character of the IKr current in individual
cardiac myocytes, and may considerably contribute to the ac-
tion potential prolongation effect of this drug (Abbott et al.,
1999; Kupershmidt et al., 2003; McDonald et al., 1997; Weerapura
et al., 2002).
Unlike dofetilide, cisapride, and sotalol, terfenadine in spite
of inhibiting IKr had no prolonging effect—even at a high con-
centration—on APD, which may relate to its blocking effects on
other ion channels, such as L-type Ca2þ and late Naþ currents
found in our study, which is the first to report the effect of terfe-
nadine on INaL. Other studies have also described that terfena-
dine inhibited not only hERG current but also Ito, ICa, and
especially INa in cardiac myocytes (Ducic et al., 1997;
Hondeghem et al., 2011; Lu and Wang, 1999).
Similarly to terfenadine, verapamil did not lengthen the ac-
tion potential duration. It is known for a long time that verapa-
mil is a Ca-antagonist and as such it blocks L-type Ca2þ current
(Ehara and Daufmann, 1978; Kohlhardt et al., 1972). Zhang et al.
(1997) found that application of verapamil at 1 and 5 mM induced
Figure 5. Effect of verapamil on hERG and IKr current. A, Representative hERG current sweeps obtained from HEK-hERG cell treated with 300 nM verapamil at room tem-
perature (RT). B, Effect of 300 nM verapamil on hERG current at 37C. C, Representative IKr current curves obtained from rabbit left ventricular muscle cell treated with
300 nM verapamil. The currents were recorded using the voltage protocols shown at the top of panels (A–C). D, Concentration-response curves of verapamil obtained
from hERG experiments at RT and at 37C using automated patch-clamp technique and from IKr measurements. Abbreviations: APC, automated patch-clamp; MPC,
manual patch-clamp.
Table 1. IC506SEM Values of Inhibitors (Dofetilide, Cisapride, Sotalol, Terfenadine, and Verapamil) Obtained in hERG Assay on Room
Temperature (RT), on Physiological (37C) Temperature and Manual hERG Measurement at 37C; and in IKr Assay at 37C
Dofetilide (nM) Cisapride (nM) Sotalol (mM) Terfenadine (nM) Verapamil (nM)
hERG APC RT 8.460.2 (n ¼ 6) 47.564.8 (n ¼ 5) 773.76 9.3 (n ¼ 5) 266.06 26.8 (n ¼ 5) 344.9626.1 (n ¼ 5)
hERG APC 37C 7.360.2 (n ¼ 5) 17.762.9 (n ¼ 5) 342.86 24.8 (n ¼ 5) 165.46 24.5 (n ¼ 5) 213.6622.5 (n ¼ 5)
hERG MPC 37C — — 77.56 4.8 (n ¼ 3–7) 31.06 3.2 (n ¼ 3–5) —
IKr MPC 37C 13.062.6 (n ¼ 3–4) 26.464.5 (n ¼ 3–5) 51.66 8.8 (n ¼ 2–6) 54.36 5.2 (n ¼ 3–4) 268.2611.3 (n ¼ 4–5)
Abbreviations: APC, automated patch-clamp; MPC, manual patch-clamp.
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dual changes in repolarization, prolonging APD90 at 1 mM, and
shortening at 5 mM in guinea-pig isolated myocytes, however,
Chen and Gettes (1979) reported that verapamil did not influ-
ence APD in guinea-pig and dog papillary muscles. In our study,
the ICaL blocking property of verapamil found to be similar or
even weaker than the IKr blocking potency of the drug. INaL was
not affected by verapamil in our experiments, similarly to ear-
lier studies reporting that verapamil at similar concentration
range did not influence fast Naþ current (Chen and Gettes, 1979;
Rosen et al., 1975).
Therefore, the multichannel blocking property of terfena-
dine and verapamil might explain the lack of action potential
prolonging effect of these drugs. It is interesting that dofetilide,
cisapride, and sotalol produced a more excessive lengthening of
APD in rabbit ventricular tissue preparations compared with
that found in human. Thus, there may be species differences in
the effects of IKr blockade, which emphasizes the importance of
species model selected for a safety pharmacological study. The
expression level and properties of cardiac ion channels are var-
ied in different species that should be taken into account when
extrapolating the results from animal models of proarrhythmia
to humans. Some studies (Jonsson et al., 2012; Liang et al., 2013;
Scheel et al., 2014) using a relatively new approach, the human
stem cell-derived cardiomyocytes, and recently 2 other papers
(Page et al., 2016; Qu et al., 2018) that applied the conventional
microelectrode technique in human ventricular trabeculae in-
vestigated possible pro-arrhythmia risk of several drugs includ-
ing dofetilide, cisapride, terfenadine, sotalol, and verapamil.
Our action potential data obtained from human preparations
are in good agreement with the results of Qu et al. (2018) except
Figure 6. The effects of 13 nM dofetilide (A), 52 lM sotalol (B), 26 nM cisapride (C), 54 nM terfenadine (D), and 270 nM verapamil (E) on action potential waveform of
rabbit ventricular muscle at basic cycle length of 1000 ms.
Table 2. The Electrophysiological Effects of 13 nM Dofetilide (n ¼ 7), 26 nM Cisapride (n ¼ 6), 52 lM Sotalol (n ¼ 5), 54 nM Terfenadine (n ¼ 8),
and 270 nM Verapamil (n ¼ 5) in Rabbit Ventricular Muscle Preparations at Basic Cycle Length of 1000 ms
RP (mV) APA (mV) Vmax (V/s) APD90 (ms) APD90 (%) APD50 (ms)
Control 88.360.3 109.06 2.4 182.1612.4 190.5614.1 154.7615.1
Dofetilide 13 nM 87.660.8 109.36 3.5 187.0615.9 285.9640.1* 47.8612.9 234.4638.2*
Control 89.760.6 105.16 2.0 139.7614.0 184.766.9 143.067.7
Cisapride 26 nM 88.761.3 105.76 1.7 129.3614.8 310.7620.7* 68.4610.0 236.3618.3*
Control 90.160.7 103.46 1.9 170.5615.3 156.9610.7 116.6613.1
Sotalol 52 lM 91.860.6 105.86 3.1 205.3621.6 244.3615.9* 56.064.6 181.3621.5*
Control 91.560.6 111.96 1.9 179.9610.5 205.469.1 170.169.0
Terfenadine 54 nM 91.161.2 113.76 2.3 201.5618.5 209.1613.7 1.463.0 174.5613.0
Control 84.162.2 104.76 2.9 129.3613.8 176.6611.5 139.5613.1
Verapamil 270 nM 81.662.2 105.86 1.9 121.9612.1 177.3612.6 0.661.8 137.2614.0
Results are means6SEM. *p < .05.
Abbreviations: APA, action potential amplitude; APD90 and APD50, action potential durations at 50% and 90% of repolarization; RP, resting potential; Vmax, maximum
rate of depolarization.
374 | EVALUATION OF PROARRHYTHMIC POTENCY
D
ow
nloaded from
 https://academ
ic.oup.com
/toxsci/article-abstract/168/2/365/5250700 by H
ungary EISZ C
onsortium
 user on 26 April 2019
for cisapride. Qu et al. (2018) reported that 30 nM cisapride
slightly (by 8%) shortened the action potential. Page et al. (2016),
however, described similar results with dofetilide, sotalol, and
verapamil to that found in this study. Therefore, human ex vivo
models using native human ventricular preparations would
generate more reliable and predictive data on proarrhythmic
adverse effects at the preclinical stage of drug development
(Page et al., 2016).
As the hERG assay is pulse protocol sensitive, longer pulses
and higher frequency would potentiate the drug binding to the
channel increasing the potency of the drug depending on the
onset and offset kinetics of the compound (Kirsch et al., 2004).
Therefore, a shorter impulse, such as an action potential, which
is only about 200 ms long in rabbit heart, might decrease the
chance of drug binding influencing negatively the potency of a
particular drug during action potential measurements.
Another factor might affect the potency of a drug is that dur-
ing these experiments the drug must penetrate into the tissue
preparation to exert its effects. Slow diffusion of drug in the tis-
sue may result in low tissue concentration, which impairs the
effect of a particular drug on action potential repolarization.
These additional factors may offset repolarization lengthen-
ing of terfenadine and verapamil. INa blockade of the terfena-
dine can impair impulse conduction, thus evoke ventricular
fibrillation, related to a noticeable widening of the QRS complex,
without significant prolongation of QT intervals (Hondeghem
et al., 2011; Lu et al., 2012). In this context it has to mention that
in this manuscript we did not focus on the accuracy of
Figure 7. Effect of 54 nM terfenadine and 270 nM verapamil on INaL current in rabbit ventricular myocytes. A, Applied voltage protocol. B, Original current traces show
that 54 nM terfenadine excessively reduced INaL, whereas 20 lM TTX completely blocks the current. C, TTX sensitive current traces in control conditions and after appli-
cation of 54 nM terfenadine (top) and 270 nM verapamil (bottom). D, TTX sensitive current (INaL) in the absence and presence of 54 nM terfenadine (left) and 270 nM ve-
rapamil (right) at the test potential of 20 mV. Values are means 6 SEM, n ¼ 4, *p < .05.
Figure 8. Effect of 54 nM terfenadine and 270 nM verapamil on the L-type ICa in rabbit ventricular myocytes. A, Voltage protocol. B, Original current traces recorded in
control conditions and in the presence of 54 nM terfenadine (top) and 270 nM verapamil (bottom). C, Current-voltage relationship of ICaL in the absence and presence of
54 nM terfenadine (top) and 270 nM verapamil (bottom). Values are means6 SEM, n ¼ 5, *p < .05.
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predictability of drug-induced TdP or ventricular fibrillation.
Other recent well-demonstrated studies strongly suggest that
other factors than potassium ion channel inhibition such as
Triangulation of action potential waveform, Reverse use depen-
dence, Instability, and Dispersion of repolarization defined as
TRIaD and wavelength of excitation (k) defined as CV (conduc-
tion velocity) multiplied by the effective refractory period (ERP)
are also important to properly assess drug-induced arrhythmia
propensity (Hondeghem, 2008a,b). In our work, we only would
like to present further arguments regarding the shortcomings of
the widely used hERG screening for arrhythmia predictability.
According to our research, native IKr assay shows better cor-
relation with APD than hERG measurements and it seems a
better tool in evaluation of cardiac proarrhythmic risk.
Although it is generally accepted that the most common
electrophysiological mechanism for drug-associated cardiac
proarrhythmic and sudden death risks result from blocking IKr,
accordingly, inhibition of IKr current is considered a primary de-
tector for proarrhythmic liability, the possibility of inhibition of
other potassium currents such as IK1 and IKs cannot be
neglected. It was shown that malfunction of those latter ion
channels can cause latent and manifest LQT syndromes
(Cubeddu, 2016). Also blocking these Kþ channels may not result
in marked repolarization lengthening but by decreasing the re-
polarization reserve they greatly increase dispersion of repolari-
zation and thereby enhancing proarrhythmic risk (Biliczki et al.,
2002; Roden, 2008; Roden and Yang, 2005). Therefore, careful
safety pharmacological testing should also include preparation
where the repolarization reserve had been previously attenu-
ated to reveal this apparently silent proarrhythmic risk. It
Figure 9. The effects of 10 nM dofetilide (A), 30 lM sotalol (B), 30 nM cisapride (C), 1 lM terfenadine (D), and 300 nM verapamil (E) on action potential waveform in undis-
eased human ventricular muscle at basic cycle length of 1000 ms.
Table 3. The Electrophysiological Effects of 10 nM Dofetilide (n ¼ 7), 30 nM Cisapride (n ¼ 3), 30 lM Sotalol (n ¼ 6), 1 lM Terfenadine (n ¼ 3), and
300 nM Verapamil (n ¼ 3) in Human Ventricular Muscle Preparations at Basic Cycle Length of 1000 ms
RP (mV) APA (mV) Vmax (V/s) APD90 (ms) APD90 (%) APD50 (ms)
Control 86.96 1.3 110.16 1.4 295.56 35.7 239.46 9.8 180.066.7
Dofetilide 10 nM 87.46 0.8 110.96 2.6 263.46 28.9 287.66 13.6* 20.464.5 206.667.9*
Control 83.76 5.0 103.36 2.5 265.96 71.0 260.76 17.8 180.4619.8
Cisapride 30 nM 83.96 3.5 102.36 1.8 269.86 61.8 334.66 42.1 27.569.8 224.6622.2
Control 89.76 1.0 119.26 2.0 230.86 21.3 301.86 19.7 233.0617.4
Sotalol 30 lM 88.86 1.5 119.26 2.4 250.06 21.1 387.06 27.6* 28.061.8 281.0620.1*
Control 84.86 1.9 109.76 3.2 275.96 26.6 269.76 12.7 208.7610.3
Terfenadine 1 lM 84.66 1.7 112.46 3.0 325.26 34.6 256.76 16.6 5.061.7 192.069.4*
Control 87.86 2.8 99.16 7.8 203.26 63.3 262.16 17.2 194.4616.5
Verapamil 300 nM 90.76 0.8 101.56 6.3 213.36 61.1 270.76 11.2 3.662.7 199.9612.4
Results are means6SEM. *p < .05.
Abbreviations: APA, action potential amplitude; APD90 and APD50, action potential durations at 50% and 90% of repolarization; RP, resting potential; Vmax, maximum
rate of depolarization.
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should be kept in mind that drug-induced proarrhythmic events
may have very low incidence (1:10 000–1:100 000) suggesting
that multiple channel hits can be 1 possible explanation
(Hancox et al., 2008; Lengyel et al., 2007; Varro and Baczko, 2011;
Yap and Camm, 2003). However, drugs, such as amiodarone or
ranolazine can induce large action potential lengthening and
QT prolongation with a concomitant reduction of the dispersion
of repolarization in the ventricle decreasing the risk of arrhyth-
mia. It is most likely due to the multichannel (IKr, IKs, INa, and
ICaL) blockade of these drugs especially inhibition of the late INa,
which current is more prominent in the midmyocardial cells
and in Purkinje fibers (Antzelevitch et al., 2004). In other words,
complex multichannel interactions of drugs with other cardiac
ion channels can also contribute to their proarrhythmic
effects—but also sometimes tend to mitigate the proarrhythmic
effect of IKr current blockade—thus action potential and in vivo
cardiac electrophysiological measurements also should be an
integral part of proarrhythmic pharmacological safety drug
tests, the single ion channel approach is not recommended.
Moreover, in vitro and in vivo studies with reduced repolarization
reserve are also essential, adding another level to the cardiac
safety pharmacology.
In conclusion, results obtained with automated patch-clamp
equipment in HEK-hERG cells usually show a reasonable confor-
mity with outcomes of IKr current and action potential experi-
ments. However, important and not well understood
differences exist between the evaluation of hERG-blocking abil-
ity with automated patch-clamp and other techniques such as
the IKr, action potential, and ECG measurements. Therefore, car-
diac safety is more accurately evaluated using all these meth-
ods simultaneously. The application of high-throughput hERG
channel screening as the only or predominant method is not
recommended because it may discredit otherwise valuable lead
molecules and/or may not detect properly the proarrhythmic
potentials of others. This study would like to draw the attention
to the limitations of the single ion channel approach especially
using high-throughput screening. In recent years, great efforts
have been made on improving the assessment of drug-
associated TdP risk. The purpose of the comprehensive in vitro
proarrhythmia assay is to avoid the misidentification of proar-
rhythmic potential of drugs based only on hERG and QT investi-
gations (Sager et al., 2014). This new paradigm consist of 4
components: an ion channel panel measured in heterologous
expression systems, in silico action potential models, human-in-
duced pluripotent stem cell-derived cardiomyocyte assay, and
human phase 1 ECGs. Based on our studies, characterization of
electrophysiological effects of drugs and drug candidate mole-
cules on native ion channels and animal or especially human
ex-vivo action potential models are also important, and may
contribute to the understanding of the complex proarrhythmic
mechanisms. However, additional studies with much larger set
of compounds are needed to infer the true predictivity of the in-
tegrated hERG, IKr, and AP/ECG assays.
Limitation of the Study
Important transmural and regional differences in current densi-
ties and in ion channel subunit protein expression exist within
the heart. However, in our study ion currents were measured in
single myocytes (mainly midmyocardial) isolated from left ven-
tricular tissue, but action potentials were recorded from right
ventricular subendocardial tissue. The reason is mainly techni-
cal. Conventional microelectrode recordings from left ventricu-
lar tissue were difficult to obtain producing a substantially
smaller success rate and left ventricular subendocardial tissue
more likely to be contaminated by subendocardial Purkinje
cells, which electrotonically influence the recordings and ham-
per pharmacologic investigations.
Another issue is the problem of species differences. Most of
our experiments were performed in rabbit. However, the action
potential waveform in rabbit is similar to that of human but the
current density, kinetical properties and even the type of chan-
nel subunits in rabbit may be different from those in human,
which may influence the drug effects on action potential and
repolarization.
The third factor is that experimental conditions such as
voltage protocol, stimulation frequency, exposure time of the
drug, and temperature may affect the action of drugs. If the
particular drug rate- or voltage-dependently block the chan-
nel its potency in patch-clamp experiments may diverged
from that measured in physiological conditions in cardiac
muscle.
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